Clinical trials: Immunosuppression For Disease
Graft-Versus-Host Disease
Bone Marrow Stromal Cell Infusions for Stem Cell Transplant Complications
Background: Bone marrow stromal cells (BMSC) from bone marrow biopsies can be used to treat disorders that cause inflammation and immune system diseases.
- Trial name
- NCT01633229
- Testing
- Bone Marrow Stromal Cell Infusion
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hepatocellular Carcinoma
Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma
The purpose of this study is to determine the safety and efficacy of sirolimus-based immunosuppressive therapy in patients following orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC), with regard to HCC…
- Trial name
- NCT00355862
- Testing
- CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free), Sirolimus
- Where
- Germany
- Volunteers
- 525 people
- Sponsor
- University of Regensburg
Bone Marrow Transplant Complications, Graft Versus Host Disease
Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
This study aims to evaluate the clinical efficacy of cyclophosphamide in patients receiving a bone marrow graft from a matched unrelated donor in overall survival, progression free survival and cumulative incidence of acute and…
- Conditions
- Bone Marrow Transplant Complications, Graft Versus Host Disease, Infection Viral, Engraft Failure
- Trial name
- NCT03818334
- Testing
- Cyclophosphamide, ATG
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Hospital Israelita Albert Einstein
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor bone marrow or stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00255710
- Testing
- filgrastim, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Kidney Transplantation, Cardiovascular Diseases
Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients
The purpose of this research study is to determine if adding or increasing the dose of CellCept while lowering the dose of tacrolimus (Prograf or Advagraf) or cyclosporine (Neoral), and/or steroids can reduce the likelihood of…
- Trial name
- MMCR (NCT01213394)
- Testing
- mycophenolate mofetil, standard immunosuppression
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Ramesh Prasad
Bronchiolitis Obliterans Syndrome, Chronic Lung Allograft Dysfunction
LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
The goal of this clinical trial is to learn about the safety and effectiveness of LAM-001 in patients who have developed bronchiolitis obliterans syndrome (BOS), a form of chronic rejection, after lung transplantation.
- Conditions
- Bronchiolitis Obliterans Syndrome, Chronic Lung Allograft Dysfunction, Lung Transplantation
- Trial name
- INSPO-BOS (NCT06018766)
- Testing
- LAM-001
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Steven Hays, MD
Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
This phase II trial studies how well sirolimus, cyclosporine and mycophenolate mofetil works in preventing graft-vs-host disease (GVHD) in patients with blood cancer undergoing donor peripheral blood stem cell (PBSC) transplant.
- Conditions
- Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Diffuse Large B-Cell Lymphoma, Adult Myelodysplastic Syndrome
- Trial name
- NCT01251575
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- 5 sites in United States, Denmark
- Volunteers
- 77 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma, Lymphoma
Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor
Primary Objective: A. To determine whether stable allogeneic hematopoietic engraftment can be safely established in patients receiving a non-myeloablative allogeneic SCT from a matched sibling donor, with fludarabine and low-dose…
- Conditions
- Multiple Myeloma, Lymphoma, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
- Trial name
- NCT00304720
- Testing
- Tacrolimus and MMF
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Colorado Blood Cancer Institute
Covid19
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V
COVID-19 (SARS-CoV2 virus) was declared a global pandemic by the WHO on 11th March 2020. Currently there are no drugs proven to prevent COVID-19 or to reduce the severity of illness if given as prophylaxis.
- Trial name
- PROTECT-V (NCT04870333)
- Testing
- Niclosamide, Ciclesonide, Sotrovimab
- Where
- 45 sites in United Kingdom
- Volunteers
- 2,240 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Immunosuppression For Disease
Drug Interaction Study With Rosuvastatin
The purpose of this study is to evaluate the effect of concomitant administration of BMS-986020 on the single dose Pharmacokinetics (PK) of Rosuvastatin in healthy subjects.
- Trial name
- NCT02101125
- Testing
- BMS-986020, Rosuvastatin
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Acute Leukemia, Acute Myeloid Leukemia
A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies
There is no curative therapy once acute leukemia patients relapse after transplant. Patients who develop clinically significant graft versus host disease (GVHD) have a lower rate of relapse than those who do not develop GVHD.
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Leukemia
- Trial name
- NCT01036009
- Testing
- Withdrawal of immunosuppression and donor lymphocyte infusion
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of California, San Francisco
Pseudophakic Bullous Keratopathy, Fuchs' Endothelial Dystrophy
The OPTIMISE Study
Rationale: The cornea is the most transplanted tissue in the Netherlands, with more than 1,500 procedures performed each year. A minimally invasive technique called Descemet Membrane Endothelial Keratoplasty (DMEK) has become the…
- Conditions
- Pseudophakic Bullous Keratopathy, Fuchs' Endothelial Dystrophy, Intraocular Pressure
- Trial name
- NCT05716945
- Testing
- Fluorometholone 0.1% Oph Susp, Dexamethasone 0.1% ophthalmic suspension, Stop steroids
- Where
- 8 sites in Netherlands
- Volunteers
- 342 people
- Sponsor
- Maastricht University Medical Center
Vaccine, Varicella-zoster Virus
Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial
Immunocompromised individuals, such as patients with multiple sclerosis (MS) or diseases of the neuromyelitis optica spectrum (NMOSD) treated with an anti-CD20 monoclonal antibody, present an increased risk of shingles.
- Conditions
- Vaccine, Varicella-zoster Virus, Multiple Sclerosis, Spectrum Disease Neuromyelitis Optica
- Trial name
- TACTIC (NCT07818356)
- Testing
- Two-dose M0-M2 vaccination schedule, Two-dose M0-M6 vaccination schedule
- Where
- 24 sites in France
- Volunteers
- 160 people
- Sponsor
- University Hospital, Toulouse